Stockscreener 앱 받기
14.55
2.48%
-0.37
시장 영업 전:
14.75
0.20
+1.37%
Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스
Canaccord reiterates Intellia stock rating on positive trial data By Investing.com - Investing.com Canada
BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Maintains Target Price $19 - Moomoo
Analysts’ Top Healthcare Picks: Intellia Therapeutics (NTLA), Electrocore (ECOR) - The Globe and Mail
Intellia Therapeutics (NTLA) Skyrockets 23% on Encouraging Lonvo-Z Results - Insider Monkey
Intellia Therapeutics Stock Jumps as CRISPR Therapy Data Put FDA Filing in Focus - TechStock²
Intellia Therapeutics jumps after additional Phase 3 HAE data and peer-reviewed publication reinforce lonvo-z outlook - Quiver Quantitative
Why is Intellia Therapeutics stock surging today? By Investing.com - Investing.com Canada
Why Is NTLA Stock Jumping 5% Premarket Today? - Stocktwits
Intellia Therapeutics | 8-K: Current report - Moomoo
NTLA Reiterated by Wedbush -- Price Target Maintained at $12.00 - GuruFocus
NTLA Reiterated by Citizens -- Price Target Maintained at $30 - GuruFocus
Intellia Therapeutics options trading jumps to 7,041 contracts - Investing.com
Intellia Therapeutics options trading jumps to 7,041 contracts By Investing.com - Investing.com India
Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Maintains Target Price $9 - Moomoo
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder - Benzinga
Intellia Reports Strong Phase 3 Results for lonvo-z, 87% fewer monthly attacks; BLA rolling, U.S. launch H1 2027 - TradingView
Phase 3 HAELO data support Intellia (NTLA) lonvo-z as potential one-time therapy - Stock Titan
Why is NTLA stock jumping 5% premarket today? - MSN
H.C. Wainwright reiterates Intellia stock rating on positive trial data - Investing.com
H.C. Wainwright reiterates Intellia stock rating on positive trial data By Investing.com - Investing.com Canada
Positive Phase III results for Intellia’s lonvo-z - The Pharma Letter
NTLA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Citizens reiterates Intellia stock rating on positive trial data By Investing.com - Investing.com Nigeria
Citizens reiterates Intellia stock rating on positive trial data - Investing.com
William Blair Maintains Intellia Therapeutics(NTLA.US) With Buy Rating - Moomoo
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
Intellia Therapeutics (NTLA) down 7.9% since last earnings report: Can it rebound? - MSN
Intellia Therapeutics (NTLA) Reports Promising Phase 3 Trial Res - GuruFocus
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits
Intellia presents Phase 3 results for HAE gene therapy lonvo-z - Investing.com UK
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema - Intellia Therapeutics
Intellia presents Phase 3 results for HAE gene therapy lonvo-z By Investing.com - Investing.com India
Intellia Therapeutics Says Haleo Met Its Primary Endpoint With An 87% Reduction (P - TradingView
One-time CRISPR gene edit cuts HAE attacks by 87% in Phase 3 trial - Stock Titan
Intellia Shareholders Back Board, Executive Pay and Auditor - The Globe and Mail
Exploring High Growth Tech Stocks In The US Market - simplywall.st
Intellia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Bhanji Muna - Moomoo
Intellia (NTLA) director receives 9,200 RSUs and 13,300 options - Stock Titan
Intellia (NTLA) director Georgia Keresty receives stock awards and options grant - Stock Titan
Intellia Therapeutics (NTLA) director receives stock and option awards - Stock Titan
Intellia (NTLA) director Brian Goff receives RSU and stock option grants - Stock Titan
Intellia Therapeutics (NTLA) director receives 9,200 RSUs and 13,300 stock options - Stock Titan
Intellia (NTLA) director awarded RSUs and stock options in new grant - Stock Titan
Intellia (NTLA) director Muna Bhanji granted 9,200 RSUs and 13,300 options - Stock Titan
Intellia Therapeutics (NTLA) posts 2026 shareholder voting results - Stock Titan
Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance Singapore
Draft FDA guidance could be a boon for gene therapy developers - MSN
Intellia Therapeutics Stock Short Interest Rises to 46.78% - Quiver Quantitative
Intellia Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Intellia Therapeutics, Inc. Trade Ideas — XETR:38I - TradingView
Average basic shares outstanding of Intellia Therapeutics, Inc. – XETR:38I - TradingView
Long term debt to total equity ratio of Intellia Therapeutics, Inc. – XETR:38I - TradingView
Diluted earnings per share (diluted EPS) of Intellia Therapeutics, Inc. – XETR:38I - TradingView
Lonvo-z Phase 3 Allergy Congress Data Might Change The Case For Investing In Intellia Therapeutics (NTLA) - Sahm
Intellia Therapeutics, Inc. (NTLA) Buy Rating Reiterated Despite Share Offering Dilution - Yahoo Finance
Understanding Momentum Shifts in (NTLA) - Stock Traders Daily
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Intellia Therapeutics
1.27%
1.43%
자본화:
|
볼륨(24시간):